Skip to content

Effects of Tulobuterol Patch (Long acting beta-2 agonist) on dyspnea during exercise in patients with COPD

Effects of Tulobuterol Patch (Long acting beta-2 agonist) on dyspnea during exercise in patients with COPD - Effects of Tulobuterol Patch in COPD

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000012795
Enrollment
10
Registered
2014-01-08
Start date
2011-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease (COPD)

Interventions

Tulobuterol Patch ADL, exercise tolerance

Sponsors

Juntendo University Faculty of Medicine and graduate School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Subjects: COPD patients COPD was diagnosed based on the patient medical history, spirometry, and radiologic findings, including high-resolution computed tomography of the chest according to Global Initiative for Chronic Obstructive Lung Disease(GOLD) guideline. Inclusion criteria included the presence of moderate to severe COPD, including post-bronchodilator forced expiratory volume in 1s (FEV1)/forced vital capacity (FVC) ratio of <70% and percent predicted FEV1 (%FEV1) <80%. Only patients whose condition had remained stable for >= 1 month more were eligible.

Exclusion criteria

Exclusion criteria: Patients with any of the following were excluded: 1)Bronchial asthma 2)Respiratory tract infection within the preceding 4 weeks 3)Respiratory failure with home oxygen therapy 4)who required oral corticosteroids 5)hypertension, heart disease, thyroid disease, diabetes, or skin disease and patients contraindicated to beta-2 agonists 6)Pregnant 7)others contraindicated to exercise

Design outcomes

Primary

MeasureTime frame
Improvement for dyspnea in COPD patients in diary living and exercise activities

Secondary

MeasureTime frame
Improvement for pulmonary function value in COPD

Countries

Japan

Contacts

Public ContactYuzo Kodama

Juntendo University Scool of Medicine Respiratory Medicine

ykodama@juntendo.ac.jp+81-3-5802-1063

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026